Skip to main content

Table 2 Summary of codeml tests for positive selection of toxins from venom-gland transcriptome in H. curtus

From: Venom-gland transcriptomic, venomic, and antivenomic profiles of the spine-bellied sea snake (Hydrophis curtus) from the South China Sea

Toxins (No.) M1: Nearly neutral -lnL M2: Positive selection -lnL M0: ω Δa P-valueb
3-FTx (1, 2, 3) p: 0.28 0.72 748.17 p: 0.17 0.39 0.45 735.24 2.81 25.86 2.4 × 10−6*
  ω: 0.00 1.00   ω: 0.00 1.00 6.13     
3-FTx (4) p: 0.26 0.74 804.61 p: 0.05 0.52 0.43 783.22 3.48 42.78 5.1 × 10−10*
  ω: 0.00 1.00   ω: 0.00 1.00 8.76     
3-FTx (5) p: 0.51 0.49 652.06 p: 0.35 0.37 0.28 632.67 2.86 38.78 3.8 × 10−9*
  ω: 0.00 1.00   ω: 0.00 1.00 9.59     
CTL (1) p: 0.30 0.70 843.02 p: 0.19 0.74 0.06 840.70 0.21 4.64 0.10
  ω: 0.00 1.00   ω: 0.00 1.00 24.33     
CTL (2) p: 0.64 0.36 1221.13 p: 0.84 0.00 0.16 1212.49 0.58 17.28 1.8 × 10−4*
  ω: 0.05 1.00   ω: 0.22 1.00 3.50     
CTL (3) p: 0.15 0.85 1160.65 p: 0.40 0.00 0.60 1148.75 2.43 23.80 6.8 × 10−6*
  ω: 0.00 1.00   ω: 0.17 1.00 4.52     
CTL (4) p: 0.53 0.47 1201.51 p: 0.50 0.44 0.07 1196.01 0.65 11.00 0.004
  ω: 0.00 1.00   ω: 0.00 1.00 4.91     
PLA2 (1) p: 0.49 0.51 978.57 p: 0.68 0.00 0.32 973.82 0.86 9.50 0.009
  ω: 0.00 1.00   ω: 0.13 1.00 3.17     
PLA2 (2, 3) p: 0.44 0.56 967.20 p: 0.60 0.00 0.40 949.47 2.08 35.46 2.0 × 10−8*
  ω: 0.00 1.00   ω: 0.00 1.00 6.87     
SVMP (1) p: 0.34 0.66 4316.80 p: 0.85 0.00 0.15 4292.41 1.08 48.78 2.6 × 10−11*
  ω: 0.00 1.00   ω: 0.57 1.00 5.53     
SVMP (2) p: 0.51 0.49 7561.33 p: 0.35 0.47 0.18 7411.20 1.30 300.26 0.00*
  ω: 0.05 1.00   ω: 0.00 1.00 5.65     
SVSP (1) p: 0.47 0.53 2042.88 p: 0.41 0.55 0.04 2028.38 0.73 29.00 5.0 × 10−7*
  ω: 0.01 1.00   ω: 0.00 1.00 7.78     
SVSP (2) p: 0.46 0.54 3659.22 p: 0.30 0.47 0.23 3579.72 2.25 159.00 0.00*
  ω: 0.00 1.00   ω: 0.00 1.00 9.49     
5NT (1, 2) p: 0.66 0.34 3064.74 p: 0.89 0.06 0.05 3057.77 0.40 13.94 9.4 × 10−4*
  ω: 0.00 1.00   ω: 0.19 1.00 6.10     
CRISP (1, 2) p: 0.43 0.57 2473.69 p: 0.28 0.56 0.16 2428.77 1.63 89.84 0.00*
  ω: 0.00 1.00   ω: 0.00 1.00 6.69     
NGF (1, 2, 3) p: 0.54 0.46 2549.71 p: 0.60 0.30 0.10 2527.86 0.86 43.70 3.2 × 10−10*
  ω: 0.12 1.00   ω: 0.28 1.00 4.35     
Cystatin p: 0.49 0.51 823.89 p: 0.93 0.00 0.07 816.20 0.94 15.38 4.6 × 10−4*
  ω: 0.00 1.00   ω: 0.48 1.00 7.57     
HA p: 0.52 0.48 3349.08 p: 0.56 0.00 0.44 3347.91 0.54 2.34 0.31
  ω: 0.00 1.00   ω: 0.00 1.00 1.28     
PDE p: 0.54 0.46 5504.07 p: 0.57 0.31 0.12 5488.82 0.65 30.50 2.4 × 10−7*
  ω: 0.00 1.00   ω: 0.00 1.00 3.57     
PLA2 inhibitor p: 0.49 0.51 1905.45 p: 0.50 0.00 0.49 1905.43 0.48 0.04 0.98
  ω: 0.00 1.00   ω: 0.00 1.00 1.06     
PLB p: 0.55 0.45 4016.84 p: 0.51 0.46 0.02 4001.61 0.58 30.46 2.4 × 10−7*
  ω: 0.00 1.00   ω: 0.00 1.00 7.11     
QC p: 0.77 0.23 2219.42 p: 0.78 0.00 0.22 2219.39 0.22 0.06 0.97
  ω: 0.00 1.00   ω: 0.00 1.00 1.08     
VEGF p: 0.38 0.62 1221.70 p: 0.64 0.30 0.05 1214.99 0.82 13.42 1.2 × 10−3*
  ω: 0.00 1.00   ω: 0.43 1.00 7.44     
  1. “*”, indicates significance at the 5% level after a Bonferroni correction
  2. a”, negative twice the difference in lnL between M1 and M2
  3. b”, P-value before correction